INTRODUCTION
Heterotrimeric G proteins transduce signals from hundreds of cell surface G protein-coupled receptors (GPCRs) to intracellular signaling networks that regulate diverse biological processes. By undergoing GPCR-stimulated guanosine diphosphate-for-guanosine triphosphate (GDP/GTP) exchange followed by GTP hydrolysis, G protein a subunits cycle between inactive GDP-bound and active GTP-bound states to determine the duration, magnitude, and specificity of biological responses (1) . In cholera, certain cancers (2), Sturge-Weber syndrome (3) , and other disorders, this cycle is disrupted by mutant or covalently modified Ga subunits that, by failing to hydrolyze GTP, are constitutively active.
Constitutively active mutant forms of Ga q or its close relative Ga 11 are the oncogenic drivers in nearly 90% of uveal melanoma (UM) patients (4) (5) (6) . UM is the most common cancer of the eye, and the eye is the second most common site of melanoma. Regardless of primary tumor treatment, nearly half of UM patients develop metastatic disease (7) with a mean survival of less than 1 year (8) . Therapies to treat primary tumors and treat or prevent metastatic disease are needed. Inhibitors of individual signaling pathways downstream of Ga q/11 are being studied in UM clinical trials, but all have failed thus far (9) . Thus, therapeutic approaches that directly target constitutively active Ga q/11 may be required to inhibit all necessary downstream oncogenic signaling networks.
Constitutively active Ga subunits have yet to be targeted pharmacologically in disease due to challenges analogous to those of inhibiting oncogenic Ras (10) (11) (12) . GTP hydrolysis defects would be extremely difficult to correct pharmacologically, and the high affinity of Ga subunits for GTP or GDP precludes the generation of effective competitive inhibitors of guanine nucleotide binding.
However, other evidence led us to consider that constitutively active Ga q can be targeted in UM by pharmacologically inhibiting GDP/GTP exchange. Although nucleotide exchange by soluble Ga q is very slow in vitro (13) , it is enhanced markedly by lipid membranes (14, 15) and Ric-8a (16, 17) , a nonreceptor guanine nucleotide exchange factor (GEF) and folding chaperone. Nucleotide exchange, therefore, may occur at appreciable rates in cells; however, constitutively active Ga q still would exist predominantly in the active GTP-bound state because average GTP/GDP ratios in human cells are~8:1 (18) , and GTP dissociates 10-fold slower than GDP (13) . Nevertheless, we reasoned that this equilibrium might be driven toward the GDP-bound state by inhibiting GDP dissociation, which would cause constitutively active Ga q to assemble into inactive GDP-bound Gabg heterotrimers and thereby attenuate all downstream oncogenic signaling networks.
Here, we found that constitutively active Ga q can be targeted pharmacologically in UM cells by FR900359 (FR), a naturally occurring, cyclic depsipeptide that has been shown previously to inhibit wild-type Ga q by interfering allosterically with GDP dissociation (19) (20) (21) . We show that FR can trap constitutively active Ga q in the GDP-bound state and inhibit downstream signaling in UM cells. We also show that constitutively active Ga q drives oncogenesis by a previously unknown mechanism that antagonizes epigenetic silencing. Our results suggest that targeting nucleotide exchange is a novel, general strategy for inhibiting Ga subunits in cancer and other diseases.
RESULTS
FR traps mutant, constitutively active Ga q in the GDP-bound state To determine whether constitutively active Ga q undergoes appreciable GDP/GTP exchange in cells, we investigated whether Ga q (Q209L), a common oncogenic guanosine triphosphatase-defective mutant in UM, could be trapped in the GDP-bound state by FR. The GDP-and GTP-bound states of Ga q (Q209L) were assessed by detecting interaction with Gbg subunits, which bind preferentially to GDP-loaded Ga subunits (1) , or with regulator of G protein signaling 2 (RGS2), which binds GTPloaded but not GDP-loaded Ga q (22) . To detect protein-protein interactions, we used split luciferase complementation assays (23) using click beetle green (CBG) luciferase to study activation state-dependent interaction between Ga subunits and cognate binding partners in living cells (24) or copurification with tandem affinitytagged [FLAG and StrepII (FS)] wild-type or constitutively active Ga q .
The data indicate that FR was able to trap constitutively active Ga q in the GDPbound state. Split luciferase complementation between Gb 1 /Gg 2 and wild-type or constitutively active Ga q was increased by FR [half-maximal effective concentration (EC 50 ), 3 and 9 nM, respectively; Fig. 1, A and B]. FR also increased the association between Gbg and affinity-tagged wild-type or constitutively active Ga q (19-and 9-fold, respectively), as indicated by copurification (Fig. 1C) . Conversely, FR drove constitutively active Ga q out of the active GTPbound state, as indicated by inhibition of split luciferase complementation between constitutively active Ga q and RGS2 [halfmaximal inhibitory concentration (IC 50 ), 0.4 nM; Fig. 1D ]. FR was selective for Ga q , as revealed by its lack of effect on the interaction between wild-type or constitutively active Ga 13 (Q226L) and Gb1g2 (Fig. 1A) or between constitutively active Ga 13 and the RGS domain of leukemia-associated Rho GEF (LARG) (Fig. 1D) . Thus, FR drives constitutively active Ga q from its active GTP-bound state into inactive GDP-bound Gabg complexes.
As a further test of the ability of FR to inhibit constitutively active Ga q , we measured downstream signaling. FR inhibited the induction of a transcriptional reporter driven by constitutively active Ga q (IC 50 , 1 nM; Fig. 1E ) but had no effect on the expression of the reporter when driven by constitutively active Ga 13 ( Fig. 1E) ) that are important for inhibition by YM-254890 (19) , an inhibitor nearly identical to FR. We found that single amino acid substitutions at any of these sites (R60K, V184S, and I190N) in constitutively active Ga q were sufficient to blunt the inhibitory potency of FR (IC 50 , 30 to 70 nM; Fig. 1E ), demonstrating that FR targets constitutively active and wildtype Ga q by using the same binding site.
FR inhibits Ga i1 bearing an engineered FR-binding site FR inhibits receptor-evoked signaling by wild-type Ga q and its close relatives Ga 11 and Ga 14 but not by other Ga subunits (20) . We therefore determined whether an FR-insensitive Ga subunit could be converted into an FR-sensitive form by introducing an FR-binding site. This might be possible because (i) all Ga subunits release GDP by a common allosteric mechanism (25), (ii) structural elements of the allosteric relay Fig. 1 . FR traps mutant constitutively active Ga q in the inactive GDP-bound state. (A) Split luciferase complementation assays in human embryonic kidney (HEK) 293 cells, measured as reconstitution of CBG luciferase activity normalized to cotransfected, constitutively expressed Renilla luciferase to assess the effect of FR on the activity state of Ga subunits as determined by interaction of Gb1g2 with the indicated wild-type (WT) or mutant constitutively active forms of Ga q (q) or Ga 13 (13) (Q209L and Q226L, respectively). Data are means ± SEM of three experiments. (B) Split luciferase complementation assays in HEK293 cells, as described in (A), to assess the potency of FR as a driver of interaction between Gb1g2 and wild-type or mutant constitutively active Ga q . Data are means ± SEM from three experiments. CBGC, C-terminal portion of CBG luciferase; CBGN, N-terminal portion of CBG luciferase. (C) Effect of FR treatment of HEK293 cells on copurification of endogenous Gbg with overexpressed, affinity-tagged wild-type or constitutively active Ga q (Q209L). Affinitytagged Ga q and Gbg were detected by immunoblotting (IB) with FLAG and Gb antibodies, respectively. Data shown are representative of three independent experiments. (D) Split luciferase complementation assays in HEK293 cells, as described in (A), to assess the potency of FR as an inhibitor of interaction between RGS2 and mutant constitutively active Ga q (Q209L) or between the RGS domain of LARG [LARG(RGS)] and mutant constitutively active Ga 13 (Q226L). Data are means ± SEM from three experiments. (E) Potency of FR as inhibitor of signal transduction by constitutively active Ga q or Ga 13 detected with an SRE(L) promoter-driven transcriptional reporter in HEK293 cells. Data are means ± SEM from three experiments. Constitutively active Ga q (Q209L), constitutively active Ga q bearing the indicated FR-binding site mutations, and constitutively Ga 13 (Q226L) were studied. Concentration-response curves were fit by nonlinear regression to derive EC 50 or IC 50 values, which were compared by t test. *P < 0.05, **P < 0.01 by t test; significance was confirmed using q < 0.05 or q < 0.01 by the false discovery rate (FDR) method of Benjamini and Hochberg. n.s., not significant.
include the FR-binding site (19, 25) , and (iii) FR-insensitive Ga subunits contain a similar but diverged form of the FR-binding site.
To test this hypothesis, we engineered an FR-binding site into Ga i1 by changing eight diverged amino acids to match their counterparts in the FR-binding site of Ga q , producing "G i/q " a subunits (illustrated in Fig. 2A ). We chose Ga i1 because it is insensitive to FR (20) and because its function is studied readily in biochemical and cell-based assays. As a control, we also made a Ga i/q (R54K) mutant, corresponding to a Ga q mutant that is less sensitive to FR (19) . We found that FR inhibited the rate of nucleotide exchange by Ga i/q in vitro (IC 50 , 4.6 mM), as indicated by the binding kinetics of a fluorescent, nonhydrolyzable GTP analog (BODIPY-GTPgS; Fig. 2B and fig. S1A ), which is rate-limited by GDP release. As expected, FR was >10-fold less potent toward Ga i/q (R54K) (IC 50 , 76 mM; Fig. 2B and fig. S1A ). Similarly, we found that FR inhibited Ga i/q signaling in cells. FR attenuated the ability of Ga i/q activated by cannabinoid type 1 receptors to inhibit forskolin-induced cyclic adenosine 3′,5′-monophosphate (cAMP) accumulation (IC 50 , 25 nM; Fig.  2C and fig. S2, C and D) . FR was~30-fold less potent toward Ga i/q (R54K) (IC 50 ,~800 nM; Fig. 2C and fig. S2 , C and D). Thus, FR targets Ga i/q and Ga q by using the same binding site. This finding suggests that FR-like molecules could be created to target the analogous, but distinct, binding sites of other Ga subtypes, providing a general approach to discover novel chemical probes of Ga function and potential therapeutics for various diseases.
FR targets constitutively active Ga subunits by inhibiting nucleotide exchange In principle, FR could target constitutively active Ga subunits by inhibiting nucleotide exchange or restoring GTP hydrolysis. We tested both hypotheses by using Ga i/q ; Ga q was unsuitable due to its unusual nucleotide binding properties that confound measuring GTP hydrolysis in vitro. We found that constitutively active Ga i/q (Q204L) [equivalent to Ga q (Q209L)] exhibited a severe defect in the catalytic rate of GTP hydrolysis that was not corrected by FR (Fig. 2D) , whereas wild-type Ga i/q hydrolyzed GTP effectively (Fig. 2D) . In contrast, FR effectively inhibited nucleotide exchange by constitutively active Ga i/q (IC 50 , 2.7 mM; Fig. 2E (Fig. 3A) . FR reduced IP 1 abundance in Mel202 and 92.1 cells >50-fold (Fig. 3B ) but had only modest effect (~2-fold) on OCM-1A cells (Fig. 3B) . Thus, FR markedly inhibited second messenger production driven by constitutively active Ga q in UM cells.
FR inhibits UM tumor cell proliferation and survival
During the preceding experiments, we also observed that FR treatment decreased the viability of Ga q (Q209L)-driven UM tumor cells. Quantification confirmed that FR inhibited the proliferation of Ga q (Q209L)-driven Mel202 and 92.1 UM cells (EC 50 , 6 and 2 nM, respectively; Fig. 4 , A and B), with no effect on proliferation of BRAF (V600E)-driven OCM-1A cells even when applied at a high concentration (10 mM). Flow cytometry revealed that FR induced . Concentration-response curves were fit by nonlinear regression to derive IC 50 values, which were compared by t test. *P < 0.05, **P < 0.01 by t test; significance was confirmed using q < 0.05 or q < 0.01 by the FDR method of Benjamini and Hochberg.
cell cycle inhibition (decreased fraction of S or G 2 -M phase cells) and apoptosis (increased fraction of sub-G 1 phase cells) in Mel202 and 92.1 cells but had no effect on OCM-1A cells (Fig. 4 , C and D). FR therefore inhibited the proliferation and survival of UM cells in which constitutively active Ga q is the oncogenic driver.
FR promotes melanocytic redifferentiation of UM cell lines
We observed that FR treatment caused Ga q (Q209L)-driven Mel202 and 92.1 cells to undergo morphological changes indicative of redifferentiation. FR-treated Mel202 and 92.1 cells lost spindle morphology, became flatter, and produced multiple projections when compared with , and OCM-1A cell lines; data are means ± SEM from four experiments. *P < 0.01 by t test; significance was corrected for multiple comparisons using the Holm-Sidak method. vehicle-treated cells or FR-treated OCM-1A cells (Fig. 5A) . Furthermore, FR increased melanocytic pigmentation in Mel202 and 92.1 cells as compared to vehicle-treated cells or FR-treated OCM-1A cells (Fig. 5B) . Similarly, FR increased the expression of two pigmentation enzymes [tyrosinase (TYR) and dopachrome tautomerase (DCT)] and premelanosome protein (PMEL) in Mel202 and 92.1 cells but not in OCM-1A cells (Fig. 5C) . FR increased the proportion of DCT-positive 92.1 and Mel202 cells (3.5-and 1.6-fold, respectively), TYR-positive Mel202 cells (1.8-fold), and PMEL-positive 92.1 and Mel202 cells (6.8-and 3.9-fold, respectively). Thus, FR antagonized the dedifferentiation process driven by constitutively active Ga q in UM cells.
FR alters expression of genes regulated by constitutively active Ga q in UM cells
To explore how FR regulates phenotypes of UM cells driven by constitutively active Ga q , we analyzed global gene expression by RNA sequencing (RNA-seq). Although FR caused an apoptotic response in UM cells, it did not markedly increase the expression of proapoptotic genes or decrease the expression of survival genes. Instead, FR modestly decreased the expression of two proapoptotic BCL2 family members (BBC3/PUMA by 3.5-fold and PMAIP1/NOXA by 2.5-fold; fig. S2 ). Other BCL2 family members showed insignificant changes in expression, and broader examination of apoptosis-related genes showed only small effects ( fig. S2 ). These results are consistent with evidence that intrinsic and extrinsic apoptotic pathways function independently of gene transcription (26, 27) .
Cell cycle genes were also relatively unaffected by FR, as indicated by gene set enrichment analysis (GSEA) and direct comparison of the RNAseq data ( fig. S2 ). The cyclin-dependent kinase inhibitor p21 CIP1 (CDKN1A, down threefold) showed reduced expression, and several cell cycle genes showed upward trends lacking statistical significance ( fig. S2) . Targets of E2F, a transcription factor positively regulated by cyclin-dependent kinases, were positively enriched (data file S1). These results suggest that the antiproliferative effects of FR are not mediated primarily by short-term changes in cell expression of cycle genes.
FR restores UM cell differentiation by promoting polycomb-mediated gene repression
In contrast to the results obtained for apoptosis and cell cycle genes, large changes in expression were observed for differentiation and developmental genes in FRtreated Ga q (Q209L)-driven 92.1 cells (data files S1 and S2). Results of a multidimensional gene expression analysis comparing relative patterns of expression of all genes across all samples showed that a large number of gene expression changes were associated specifically with FR treatment (Fig. 6A) . Most strikingly, a distinct gene cluster showed marked reduction in expression [4-to~160-fold; Fig. 6B (circled) and data file S3]. Among genes in this cluster, 38% are associated with cell differentiation and development, as revealed by gene ontology (GO) analysis ( Fig. 6C and data file S4) . A total of 42% of genes in this cluster are known targets of the polycomb repressive complex 2 (PRC2) during differentiation from embryonic stem cells, as indicated by GSEA (Fig. 6D and data file S5). These results were confirmed by quantitative real-time polymerase chain reaction (PCR) analysis of FR-treated 92.1 cells (fig. S3 ). In contrast, expression of PRC2-regulated genes in BRAF(V600E)-driven OCM-1A cells was unaffected by FR ( fig. S3 ), demonstrating specificity of FR for developmental and differentiation genes targeted by constitutively active Ga q in UM cells. The RNA-seq analyses suggested a novel mechanism for Ga q -induced oncogenesis in UM in which constitutively active Ga q antagonizes PRC2-mediated gene repression, thereby reactivating genes associated with stemness and driving dedifferentiation of UM cells into a more stem-like phenotype. FR treatment inhibits constitutively active Ga q , relieves blockade of PRC2-mediated repression, resilences these genes, and returns UM cells to a melanocytic state. Consistent with this hypothesis, we found that inhibiting the catalytic subunits of PRC2 complexes (EZH1/2) with GSK503 maintained 92.1 cells in an undifferentiated state and blocked the ability of FR to redifferentiate these cells, as indicated by morphology (Fig. 6E) and pigmentation (Fig. 6F) . The effectiveness of GSK503 at inhibiting histone H3 Lys 27 (H3K27) methylation was confirmed by immunoblotting histones isolated from control and FR-treated 92.1 cells (Fig. 6G) .
DISCUSSION
GDP/GTP exchange can be exploited as an Achilles heel of constitutively active Ga subunits The most important discovery provided by our studies is that GDP/GTP exchange is an underappreciated vulnerability of constitutively active Ga subunits and one that can be exploited pharmacologically in UM and other diseases. Although Ga subunits undergo GDP/GTP exchange slowly in vitro, we discovered that nucleotide exchange occurs in cells at rates sufficient for constitutively active Ga q to be trapped in the inactive GDP-bound state by treatment with FR, an allosteric inhibitor of GDP release. When trapped by FR, GDP-bound constitutively active Ga q assembles into Gabg heterotrimers, further suppressing GDP release and stabilizing the inactive state. Because FR-bound G q heterotrimers are show reduced histone H3K27 trimethylation. Plot shows relative fraction of trimethyl-histone H3K27 compared to dimethyl sulfoxide (DMSO) control and normalized to total histone H3 from densitometry data from three independent experiments. *P < 0.01 by t test; significance was confirmed using q < 0.01 by the FDR method of Benjamini and Hochberg.
refractory to activation by GPCRs (20) , signaling networks downstream of constitutively active Ga q are attenuated.
Although our study involved constitutively active Ga q in UM, we anticipate that constitutively active forms of Ga subunit subtypes that drive other types of cancer may also be vulnerable to allosteric inhibitors of GDP release. Constitutively active Ga 11 in UM (12) and Ga 14 in vascular tumors (28) should be susceptible because wild-type forms of these Ga subunits are sensitive to FR (20) . Although other subtypes of Ga subunits are insensitive to FR, all Ga subunits have a diverged but related form of the allosteric regulatory site in Ga q that binds FR. This site includes conserved features of linker 1, which stabilizes the GDP-bound state by interacting with helix 1, helix A, and helix F as part of the universal mechanism that regulates GDP release. As predicted by this hypothesis, we found that engineering an FR-binding site into an FR-insensitive Ga subunit was sufficient to confer FR sensitivity. Thus, we speculate that a collection of FR-like inhibitors, each of which selectively targets the diverged allosteric regulatory site of certain Ga subunits, may provide a novel approach toward therapeutic development in cancers associated with other mutant constitutively active Ga subunits (2), cholera, and Sturge-Weber syndrome. In addition, this approach may be efficacious for diseases that are driven by multiple GPCRs in which blocking a single receptor is ineffective.
UM cells are addicted to constitutively active Ga q
Another important discovery emerging from our study is that constitutively active Ga q has unexpectedly diverse functional roles as an oncogenic driver in UM. Instead of affecting a single-cell biological process, FR inhibits proliferation, triggers apoptosis, and drives melanocytic redifferentiation of UM cells. Our findings help to explain why previous studies using mitogen-activated protein kinase kinase, Akt, and protein kinase C inhibitors to target individual signaling pathways downstream of Ga q/11 failed in clinical trials of UM (9) . By inhibiting constitutively active Ga q and consequently attenuating all downstream signaling networks, FR or related inhibitors may impair the growth and survival of cancer cells in UM primary tumors, and they may also decrease the probability or extent of metastasis because melanocytic differentiation correlates inversely with metastatic potential in UM (29, 30) . For primary tumors, FR may slow conversion from the indolent state to aggressive class 2 tumors (31), or it may impair the growth or spread of metastatic lesions, including those that are clinically undetectable. Tumor-targeted or focal delivery of FR may be required because systemic administration might cause unacceptable side effects by inhibiting Ga q/11 in normal tissues. Nevertheless, the marked FRsensitivity of UM tumor cells driven by constitutively active Ga q suggests that clinical investigation of this or related inhibitors could be considered.
Constitutively active Ga q antagonizes gene silencing by the PRC2
We found a marked and unanticipated consequence of inhibiting constitutively active Ga q in UM-the repression of gene sets that control differentiation and development. Many of these repressed genes are involved in embryonic stem cell lineage specification and differentiation and are targets of epigenetic silencing by the PRC2, which acts through H3K27 trimethylation (32) (33) (34) . These repressed genes include ADRA2A (a 2A -adrenergic receptor) and HAND2 (heart and neural crest derivatives expressed-2). The ADRA2A gene promoter was identified in independent screens for PRC2 subunit binding and for H3K27 trimethylation (32) (33) (34) , and ADRA2A has been linked to cancer progression and severity (35) . The HAND2 gene promoter is also targeted by PRC2 binding and H3K27 trimethylation (32) (33) (34) , especially in migrating cranial neural crest cells, where HAND2 expression distinguishes neural crest cell lineages during facial development (36) .
Together, our findings reveal a novel mechanism in which signaling by constitutively active Ga q in UM cells antagonizes PRC2-mediated gene silencing, thereby maintaining UM cells in a less differentiated state similar to premelanocytic cranial neural crest cells (36) . This finding, coupled with previous studies of BAP1 (BRCA1-associated protein-1) (30, 37) , indicates that a temporal hierarchy of epigenetic regulation drives tumorigenesis and progression in UM. Early in tumorigenesis, mutations that constitutively activate Ga q are acquired, which inhibits PRC2-mediated repression. Subsequent loss of BAP1, a histone H2A(Lys 119 ) deubiquitinase that antagonizes repression by PRC1, then leads to metastasis.
MATERIALS AND METHODS

FR900359
FR was purified from Ardisia crenata according to published methods (20) . The structure of purified FR relative to a commercially available equivalent (UBO-QIC; University of Bonn, Germany) was established by nuclear magnetic resonance.
Biochemical assays
Split luciferase assays were performed as described previously (24) . The N-terminal portion of CBG luciferase (CBGN) was inserted into the aBaC loop within the helical domain of wild-type and constitutively active (c.626A>T; Q209L) mutant forms of GNAQ (Ga q ) and GNA13 (Ga 13 ) (Q226L). Insertion of foreign proteins at this site preserves Ga subunit function (38) . The C-terminal region of CBG luciferase (CBGC) was fused to the N termini of GNB1 (Gb 1 ), which was cotransfected with untagged GNG2 (Gg 2 ); RGS2; and the RGS domain of ARHGEF12 (LARG), which interacts with Ga 13 only in the active GTP-bound state (39) . HEK293 cells transiently transfected with various combinations of fusion constructs generating tagged proteins were treated for 18 hours with vehicle (DMSO) or FR, and luciferase assays were performed to measure reconstituted luciferase activity. Assays of transcriptional reporters driven by Ga subunits were performed as described previously (40) . Ga-driven firefly luciferase activity was normalized to cotransfected Renilla luciferase expressed from a constitutive promoter.
Experiments used to measure agonist-evoked inhibition of forskolininduced cAMP formation in Neuro2A cells were performed in a 96-well plate format, as described in (24) with slight modifications. Cells were transfected with a cAMP FRET reporter and PTX-resistant forms of Ga i1 , Ga i/q , or Ga i/q (R54K). After cells were treated for 16 hours with PTX (100 ng/ml) to inactivate endogenously expressed G i , FRET was used to measure inhibition of forskolin (FSK)-induced cAMP formation by a CB1 cannabinoid receptor agonist (WIN 55,212-2; WIN). A Synergy H4 hybrid plate reader (BioTek) was used to measure FRET every 57 s by exciting the FRET donor (420/20-nm bandpass filter) and simultaneously detecting donor and acceptor emissions (480/20-and 540/ 20-nm bandpass filters, respectively). FRET measurements of changes in intracellular cAMP were expressed ratiometrically as
where FRET ratio is (480-nm emission/540-nm emission) at a given time point, and the baseline FRET ratio is the average of (480-nm emission/540-nm emission) before FSK stimulation. Independent experiments were performed in triplicate. Effects of FR on agonistevoked adenylyl cyclase inhibition were quantified as the percentage of DR/Ro relative to vehicle control. FR concentration-response curves were generated by a three-parameter fit. Accumulation of IP 1 in UM cells was measured using the IP-One Kit (catalog number 62IPAPEB, Cisbio Inc.), according to the supplier's instructions. A total of 10,000 Mel 202 cells, 20,000 92.1 cells, and 20,000 OCM-1A cells were seeded into white-bottom tissue culture grade 384-well plates. After an overnight incubation, cells were treated with FR or DMSO and returned to the incubator. The next day, stimulation buffer was added for 1 hour after which IP 1 -d2 and Ab-Cryp were added, and the cells were incubated at room temperature for 60 min. Plates were read in a Synergy H4 hybrid plate reader. Standard curves were generated using reagents supplied with the kit.
Copurification of tandem affinity-tagged Ga q and endogenous Gbg was assayed as follows. A gBlock gene fragment (Integrated DNA Technologies) encoding a glycine/serine linker (GGGSSGGG) followed by a FLAG-StrepII-StrepII (FS) tag and another glycine/serine linker (GGGSSGGG) was inserted between sequences encoding amino acid residues 124 and 125 of mouse Ga q (wild-type and Q209L mutant), cloned into pcDNA3.1+, and verified by DNA sequencing. HEK293 cells were plated in 10-cm dishes and transfected the next day with the indicated plasmids. After 24 hours, transfection medium was removed and replaced with fresh media containing one FR (1 mM) or vehicle (DMSO). Twenty-four hours after treatment, media were removed, and cells were washed with Dulbecco's phosphate-buffered saline (PBS) and processed for tandem affinity purification (TAP). TAP was performed as described previously (24) with the following modifications: All subsequent steps were performed on ice or at 4°C. HEK293 cells were lysed in [50 mM tris (pH 8.0), 5 mM EDTA, 100 mM NaCl, 0.5% (v/v) IGEPAL CA-630, 1 mM MgCl 2 , and complete protease inhibitor mix (catalog number 11697498001, Roche), with or without 1 mM FR] by sonication on ice for 2 min (30 s on, 30 s off, 60% A), rotated end-over-end for 30 min, and cleared by ultracentrifugation at 100,000g for 15 min. Cleared lysates were incubated with Strep-Tactin resin (catalog number 2-1206-010, lot number 1206-0350, IBA) overnight with end-over-end rotation and washed three times in batch with 10 column volumes of wash buffer [50 mM tris (pH 8.0), 5 mM EDTA, 100 mM NaCl, 0.5% (v/v) IGEPAL CA-630, 1 mM MgCl 2 , complete protease inhibitor mix, and ±1 mM FR]. Protein complexes were eluted two consecutive times by incubating with a fivefold column volume of elution buffer [desthiobiotin buffer E (catalog number 2-1000-025, lot number 1000-5170, IBA), 0.1% (v/v) IGEPAL CA-630, 1 mM magnesium chloride, complete protease inhibitor mixture, and ±1 mM FR] for 30 min in batch. Strep-Tactin elution fractions were combined and incubated with anti-FLAG M2-Agarose (catalog number A2220, lot number SLBW1929, Sigma-Aldrich) in batch for 2 hours and washed three times in batch with a 10-fold column volume of wash buffer. Protein complexes were eluted from FLAG agarose by incubating with a fourfold column volume of FLAG elution buffer [3xFLAG peptide (200 mg/ml); catalog number F4799, lot number SLBM1190V in wash buffer, Sigma-Aldrich) for 30 min in batch. Lysates and FLAG eluates were resolved on 12% SDS-polyacrylamide gel electrophoresis (PAGE) gels and transferred to Immobilon(P SQ ) polyvinylidene difluoride (PVDF) membranes (catalog number ISEQ00010, Millipore). Membranes were blocked with 5% (w/v) milk in TBST [25 mM tris (pH 7.2), 150 mM NaCl , 2.7 mM KCl, and 0.1% (v/v) Tween 20] and incubated with primary antibodies overnight at 4°C. Lysate primary antibody mixture was ANTI-FLAG M2 (1:50,000; catalog number F1804, lot number SLBN5629V, Sigma-Aldrich) and Gb H-1 (1:500; catalog number sc-166123, lot number G2414, Santa Cruz Biotechnology). TAP eluates were probed with a primary antibody mixture consisting of anti-FLAG M2 (1:50,000; catalog number F1804, lot number SLBN5629V, Sigma-Aldrich) and anti-Gb 1 H-1 (1:500; catalog number sc-166123, lot number G2414, Santa Cruz Biotechnology). Membranes were washed with TBST at least three times and incubated with goat anti-mouse immunoglobulin G coupled to IRDye 800CW (catalog number 926-32210, lot number C70712-15, LI-COR Biosciences). After incubation, membranes were washed at least three times with TBST, and signals were detected using an Odyssey model 9120 imaging system (LI-COR Biosciences).
Nucleotide exchange by purified His-tagged Ga subunits was assayed as follows. Plasmid pet14B-6xHIS-Ga i1 was a gift from M. Linder (Cornell University, New York). A pet14B-6xHIS-Ga i/q plasmid was generated by cloning a custom synthesized gBlock gene fragment (Integrated DNA Technologies) containing mutations encoding eight amino acid substitutions (V50I, K54R, Y69F, V72L, K180P, V185I, T187Y, and H188P) in 6xHIS-Ga i1 . Site-directed mutagenesis of this plasmid was used to generate pet14B-6xHIS-Ga i/q (R54K). Recombinant His-tagged Ga subunits were expressed and purified from Escherichia coli according to published methods (41) . To detect nucleotide exchange, fluorescence of the GTP analog BODIPY-GTPgS (catalog number G22183, Thermo Fisher Scientific) was recorded with a Synergy H4 hybrid plate reader in the absence or presence of recombinant Ga subunits (42) . GraphPad Prism was used to fit fluorescence (DF/F 0 ) curves to a pseudo first-order rate equation and obtain k obs values relative to vehicle controls. FR concentration-response curves were generated by a three-parameter fit of normalized k obs values. Assays of GTP hydrolysis by His-tagged Ga i/q subunits were performed as follows. Reactions contained wild-type Ga i/q (1.5 mM) or constitutively active Ga i/q (Q204L) (3 mM) in reaction buffer [50 mM tris-HCl, 5 mM MgCl 2 , 1 mM EDTA, and 0.5 mM dithiothreitol (pH 8.0)]. Reactions performed in triplicate were started by adding reaction buffer containing g 32 P-GTP (final concentration, 100 nM; specific activity, 100 Ci/mmol). Ga subunits were present at >10-fold molar excess over GTP to assess the catalytic rather than steady-state rate of GTP hydrolysis. As indicated, vehicle (DMSO) or FR (final concentration, 25 mM) was added. Aliquots were removed at intervals, quenched by addition of 1 N formic acid, and spotted on polyethyleneiminecellulose thin-layer plates (catalog number Z122882, Sigma-Aldrich). Plates were developed in 0.5 M LiCl 2 and 0.5 M formic acid, dried, wrapped in plastic, and exposed 1 hour to a phosphor storage screen (GE Healthcare Life Sciences) that was visualized on a Typhoon FLA 9500 scanner (GE Healthcare Life Sciences) at a resolution of 100 mm and photomultiplier voltage of 750 V. Scans were analyzed using Image Studio Lite to quantify the amount of labeled GTP and orthophosphate in each lane. GTP hydrolysis was calculated by dividing the magnitude of the orthophosphate signal by the sum of the orthophosphate and GTP signals. Data were fit using GraphPad Prism to a pseudo first-order rate equation.
UM cell culture assays Cells were cultured at 37°C in 5% CO 2 . Human UM cell lines 92.1, Mel202, and OCM-1A were derived by M. Jager (Laboratory of Ophthalmology, Leiden University), B. Ksander (Schepens Eye Institute, Massachusetts Eye and Ear Infirmary), and J. Kan-Mitchell (Biological Sciences, University of Texas at El Paso). UM cell lines were grown in RPMI 1640 medium (Life Technologies), supplemented with 10% fetal bovine serum and antibiotics. Cell viability was measured using a watersoluble tetrazolium salt, WTS-8 (Bimake), following the manufacturer's protocol. Flow cytometry for analysis of cell proliferation and apoptosis was performed at the Siteman Cancer Center Flow Cytometry Core on a FACScan analyzer (BD Biosciences) using a standard propidium iodide staining protocol, as described previously (43) .
Immunofluorescence staining of UM cell lines was carried out by adding an equal volume of 2× fixative (PBS with 4% paraformaldehyde and 0.4% glutaraldehyde) to UM cells in RPMI 1640 growth medium. After 15 min at 37°C, cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min, washed with PBS, and blocked with 2% fish gelatin (Sigma-Aldrich) in PBS. Primary and secondary antibodies were diluted in 2% fish gelatin in PBS. Primary antibodies included mouse monoclonal anti-premelanosomal protein (One World Lab), rabbit polyclonal anti-TYR (One World Lab), rabbit polyclonal anti-DCT (One World Lab), rabbit polyclonal anti-S100 (DakoCytomation), and mouse monoclonal anti-BrdU (Life Technologies). Secondary antibodies were Alexa Fluor conjugates (Life Technologies), and the mounting agent was ProLong Gold (Life Technologies). Cell morphology was assessed by phasecontrast imaging with an inverted microscope (Olympus IX72) using a 10× objective. Images were analyzed to compare the percentage of cell populations that were positive for a given marker in representative fields from three independent samples. Significant difference relative to vehicle control was defined as P < 0.01 by Fisher's exact test for all comparisons.
Immunoblotting of UM cell lines was performed by lysing cells in a radioimmunoprecipitation assay buffer [150 mM sodium chloride, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and 50 mM tris (pH 8.0)] with 1× complete protease inhibitor mix (catalog number 11697498001, Roche). Cleared lysates were analyzed by immunoblotting, as described above for HEK293 cells.
Histones were isolated from UM cell lines by using the Active Motif Histone Purification Mini Kit (catalog number 40026, Active Motif). Lysates were resolved on 15% SDS-PAGE gels and transferred to an Immobilon(P) PVDF membrane (catalog number IPVH00010, Millipore). Membranes were blocked with 5% (w/v) milk in TBST [25 mM tris (pH 7.2), 150 mM NaCl, 2.7 mM KCl, and 0.1% (v/v) Tween 20] and incubated with primary antibodies. Membranes were washed with TBST at least three times and incubated with IRDye 680-coupled goat antirabbit and IRDye 800 or goat anti-mouse antibodies (LI-COR Biosciences). After incubation, membranes were washed at least three times with TBST, and signals were detected using Odyssey model 9120 imaging system (LI-COR Biosciences). Other primary antibodies used for immunoblotting were anti-EE (catalog number MMS-115P, lot number E12BF00285, Covance), anti-actin C4 (catalog number MAB1501, Millipore), antihistone H3 (clone A3S; catalog number 05-928, MIllipore), and antihistone H3-trimethyl-K27 (catalog number 6002, Abcam).
Statistical analyses
All statistical analyses were performed with GraphPad Prism. For split luciferase complementation assays, IP 1 assays, and viability assays, cells were plated in triplicate wells and treated in parallel (technical replicates), and each experiment was performed three times on different days (biological replicates). Mean values and SEMs were calculated from at least nine replicate values for each condition, and t tests were performed comparing each condition to controls to determine statistical significance of FR treatment. For guanine nucleotide exchange and GTP hydrolysis assays, experiments were performed in triplicate, and each experiment was performed at least three times on different days with different protein preparations. Mean values and SEMs were calculated from at least nine replicate values for each condition, and t tests were performed comparing each condition to controls to determine statistical significance of FR treatment. For FRET reporter assays, FRET fluorescence signals were quantified relative to vehicle controls from three independent experiments, and mean values and SEM were calculated from the combined data of three experiments. IC 50 values and confidence intervals were calculated by the least-square nonlinear curve-fitting method for normalized response to FR. For histone methylation assays, densitometry was performed on immunoblots for trimethyl-histone H3K27 and compared to DMSO control and normalized to total histone H3 from three independent experiments. The statistical significance of response to FR treatment was determined with t tests.
Gene expression analysis 92.1 UM cells were treated with 100 nM FR or vehicle (DMSO) in RPMI growth medium and collected after 1 and 3 days of treatment. RNA was isolated using the RNeasy Mini Kit (QIAGEN) following the manufacturer's protocol and including the optional DNase I treatment step. RNA quality was assessed on a Bioanalyzer 2100 (Agilent Technologies). mRNA was extracted from total RNA using a Dynal mRNA Direct kit, fragmented, and reverse-transcribed to double-stranded complementary DNA with random primers before addition of adapters for library preparation. Library preparation and HiSeq 2500 sequencing were performed by the Washington University Genome Technology Access Center (gtac.wustl.edu). FastQ files were aligned to the transcriptome and the whole genome with STAR (Spliced Transcripts Alignment to a Reference). Biologic replicates were simultaneously analyzed by edgeR and Sailfish analyses of gene-level/exon-level features. Unexpressed genes and exons were removed from the analyses. Unsupervised principal component analysis and volcano plots were generated in Bioconductor using edgeR. Significance Analysis of Microarrays version 4.0 was used to generate a ranked gene list, and a threshold of q < 10% and a fold change of >2.0 were then used to select the most highly statistically significant genes that showed reduced expression in FR-treated versus vehicle control cells. This list was used as signature gene sets for GO analysis and GSEA (44) . GO groups were assembled by merging the lists of genes from related GO terms that were significantly enriched (P < 0.01 using the Kolmogorov-Smirnov statistic) in the signature gene set. Significant gene sets (P < 0.01 using the Kolmogorov-Smirnov statistic) from GSEA analyses were combined such that genes associated with multiple related signatures were only counted once and each gene was assigned only to a single combined group based on the signature with the highest enrichment score for that gene. Gene expression changes were validated in all three UM cell lines by quantitative PCR using fast SYBR Green Master Mix (Thermo Fisher Scientific), following the manufacturers' protocol. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as an endogenous control. Primer sets used for the assay are listed in data file S6.
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